Cellivery, Up 29.99% on Rising Theme of COVID-19 (Therapeutics/Vaccine Development)

On the 25th, the COVID-19 (treatment/vaccine development, etc.) theme rose by 3.05% compared to the previous day, showing strength, while Cellivery, a related stock attracting attention, surged by 29.99% compared to the previous day.

[Graph] Major stock price changes in the COVID-19 (treatment/vaccine development, etc.) theme

According to provisional data compiled at 10:56, foreign investors are net selling 5,000 shares of Cellivery.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)

According to the analysis by Thinkpool Robo Algorithm RASSI, Cellivery’s quant financial score is 10.23 points, showing higher growth and stability scores than the average of other stocks related to COVID-19 (treatment/vaccine development, etc.), but its quant financial ranking was only 18th out of 27 stocks. On the other hand, United Pharm ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to other stocks.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of analysis by the Robo Algorithm based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.